Drugs & Targets Rafael Pharmaceuticals receives FDA Orphan Drug Designation of CPI-613 for peripheral T-cell lymphoma September 07, 2018Vol.44 No.33
Drugs & TargetsFree Imbruvica + rituximab becomes first non-chemo combination for Waldenström’s macroglobulinemia August 31, 2018Vol.44 No.32
Drugs & TargetsFree FDA approves lenvatinib for unresectable hepatocellular carcinoma August 31, 2018Vol.44 No.32
Drugs & TargetsFree Lenvima gets European approval for advanced, unresectable hepatocellular carcinoma August 31, 2018Vol.44 No.32
Drugs & TargetsFree FDA approves pembrolizumab + chemo for first-line metastatic non-squamous NSCLC August 31, 2018Vol.44 No.32
Drugs & TargetsFree FDA updates prescribing information for Keytruda, Tecentriq August 31, 2018Vol.44 No.32
Drugs & TargetsFree Nivolumab gets accelerated approval for third-line metastatic small cell lung cancer August 31, 2018Vol.44 No.32
Drugs & TargetsFree FDA approves Kyowa Kirin’s Poteligeo for mycosis fungoides and Sézary Syndrome August 31, 2018Vol.44 No.32
